Author, year | No. of participants | Age Mean (SD) | Sex Female/male | Diagnosis | Treatment setting and regimens | Performance status | Comorbidities |
---|---|---|---|---|---|---|---|
Arrieta et al [30], 2019 | Total: 301 (300 analyzed) IG: 150 CG: 150 | IG: 76.8 (5.1) CG: 76.6 (5.0) | 180/120 60%/40% | Various cancers (colon, rectum, breast, esophagus, oral, kidney, prostate, bladder, lung, stomach, biliary ducts, ovary, hepato-cellular carcinoma, lymphoma, womb, endometrium, and pancreas) Cancer stage: NR | Curative treatments Systemic treatments: chemotherapy (60%), endocrine therapy (20%), targeted therapy (2%) | By ECOG PS 0: 53% PS 1: 30% PS 2: 4% NR: 13% | By CIRS-G: No grade 3–4 comorbidities: 79% 1 grade 3–4 comorbidity: 17% ≥2 grade 3–4 comorbidities: 4% |
Maréchal et al [31], 2019 | Total: 14 IG: 6 CG: 8 | IG: 67.7 (2.1) CG: 69.6 (4.1) | 11/3 79%/21% | Breast and colon cancer Cancer stage: NR | Systemic oncological treatment that started ≤12 weeks (treatment setting not further reported) | NR | NR |
Sajid et al [32], 2016 | Total: 19 EXCAP: 6 Wii: 8 CG: 5 | EXCAP: 75.7 (9.5) Wii: 77.5 (6.7) CG: 71.8 (5.0) | 0/19 0%/100% | Prostate cancer Cancer stage: NR | Treatment with ADT for ≥3 months Treatment setting: stable diseasea | By Karnofsky, mean (SD): EXCAP: 88.3 (13.3) Wii: 87.5 (8.9) CG: 88 (16.4) | No. of comorbidities: EXCAP; 0–1: 67%, 2: 33% Wii; 0–1: 75%, 2: 25% CG; 0–1: 60%, 2: 40% |
Miki et al [33], 2014 | Total: 78 IG: 38 CG: 40 | IG: 73.0 (4.6) CG: 75.5 (6.6) | 43/35 55%/45% | Breast and prostate cancer Cancer stage: IG: Stage I: 28.9% Stage II: 57.9% Stage III: 2.6% Stage IV: 10.5% CG: Stage I: 32.5% Stage II: 37.5% Stage III: 12.5% Stage IV: 17.5% | Curative and palliative treatments Systemic treatment: endocrine therapy (53%), chemotherapy (6%) | NR | NR |